Form 4: AngioDynamics Director Karen Licitra Receives Annual Stock Compensation
Statement of Changes in Beneficial Ownership
AngioDynamics, Inc. Director Karen A. Licitra acquired 17,675 shares of common stock as part of her regular annual compensation, bringing her total beneficial ownership to 90,435 shares.
Summary
- Karen A. Licitra, a Director of AngioDynamics, Inc. (ANGO), acquired 17,675 shares of common stock.
- The acquisition occurred on July 16, 2025.
- These shares represent restricted stock units granted as regular annual compensation for her service as a director.
- The restricted stock units vested immediately upon grant.
- Following this transaction, Ms. Licitra beneficially owns 90,435 shares of AngioDynamics common stock directly.
- The shares were acquired at a price of $0, which is typical for RSU grants.
Sentiment
Score: 7
Explanation: The grant of restricted stock units to a director as regular compensation is a positive sign of ongoing commitment and alignment, though it's a routine event and not indicative of extraordinary news.
Positives
- The grant of restricted stock units to a director indicates ongoing commitment and alignment of interests between the board and shareholders.
- The immediate vesting of the restricted stock units provides immediate ownership to the director.
Future Outlook
The document does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This Form 4 filing is specific to insider compensation and does not provide broader industry context or trends.
Comparison to Industry Standards
- This filing is a standard disclosure of director compensation via restricted stock units, which is a common practice across industries for aligning director interests with shareholders. No specific comparable companies or projects are mentioned to assess against global benchmarks.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Substitute Power of Attorney Appointment | Stephen A. Trowbridge, an attorney-in-fact for Karen A. Licitra, appointed Lawrence T. Weiss as a substitute attorney-in-fact to handle SEC filings (Forms 3, 4, and 5) on behalf of Ms. Licitra. This supersedes any prior substitute powers of attorney. | 2025-01-20 | This change streamlines the administrative process for SEC filings for the reporting person and does not indicate a substantive change in corporate governance or Ms. Licitra's role. |
Related Party Transactions
- The transaction involves compensation to a director, which is a related party transaction, but it is a standard form of compensation and not an unusual dealing.
Stakeholder Impact
- Shareholders: The grant of restricted stock units aligns the director's interests with shareholders by tying compensation to company stock performance.
Key Dates
| Date | Description |
|---|---|
| 2025-01-20 | Date Stephen A. Trowbridge executed the Substitute Power of Attorney appointing Lawrence T. Weiss. |
| 2025-07-16 | Date of transaction: Acquisition of 17,675 restricted stock units by Karen A. Licitra. |
| 2025-07-18 | Date the Form 4 filing was signed by Lawrence T. Weiss, Attorney in Fact. |
Keywords
AngioDynamics, ANGO, SEC Form 4, Director Compensation, Restricted Stock Units, RSU Grant, Beneficial Ownership, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.